Patents Examined by Samantha Shterengarts
  • Patent number: 9963424
    Abstract: Here described are compounds of formula I: wherein R1 and R2 are independently selected from C10 to C18 alkyl, C12 to C18 alkenyl, and oleoyl; R3 and R4 are independently selected from C1 to C6 alkyl and C2 to C6 alkanol; X is selected from —CH2—, —S—, and —O—, or X is absent; Y is selected from —(CH2)n, —S(CH2)n—, —O(CH2)n—, -thiophene-, —SO2(CH2)n—, and ester; n=1-4; a=1-4; b=1-4; c=1-4; and Z? is a counterion. Also described herein are compositions and pharmaceutical formulations including compounds of formula I which are useful for the delivery of therapeutic agents, and methods of using these compositions and formulations.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: May 8, 2018
    Assignee: Nitto Denko Corporation
    Inventors: Yoshiro Niitsu, Victor Knopov, Joseph E. Payne, Zheng Hou, John A. Gaudette, Violetta Akopian, Richard P. Witte, Mohammad Ahmadian, Loren A. Perelman, Yasunobu Tanaka, Priya Karmali, Sridhar C. Nagarajan
  • Patent number: 9937143
    Abstract: The present invention relates to the NEP inhibitor pro-drug N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid ethyl ester, or a pharmaceutically acceptable salt thereof; or the NEP inhibitor N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid, or a pharmaceutically acceptable salt thereof, pro-drug for use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling; a method for treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of the NEP inhibitor or the NEP inhibitor pro-drug, or a pharmaceutically acceptable salt pro-drug thereof, to a subject, e.g. a human subject, in need of such treatment.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: April 10, 2018
    Assignee: Novartis AG
    Inventors: Christoph Schumacher, Thomas Holbro
  • Patent number: 9938234
    Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: April 10, 2018
    Assignees: Salk Institute for Biological Studies, Mitobridge, Inc.
    Inventors: Ronald M. Evans, Michael Downes, Thomas J. Baiga, Joseph P. Noel, Emi Kanakubo Embler, Weiwei Fan, John F. W. Keana, Mark G. Bock, Arthur F. Kluge, Mike A. Patane
  • Patent number: 9933419
    Abstract: The present invention provides small molecule compounds that can form covalent adducts with specific sequences of RNA, such as the hairpin loop r(CUG)exp sequence which is a cause of myotonic dystrophy type 1 (DM1), or the r(CGG)exp sequence which is a cause of fragile X-associated tremor/ataxia syndrome (FXTAS); to methods of making the small molecule compounds; and to methods of using the small molecular compounds in the treatment of DM1 or of FXTAS in patients afflicted therewith. The invention further provides a method for identifying an RNA target of a small molecule drug in vivo, using a small molecule drug conjugated to an RNA-reactive crosslinker group and a reporter group, contacting a cell or nucleic acid extract with the small molecule drug conjugate, then separating RNA targets crosslinked to the small molecule drug conjugate by interaction of the affinity group with a complementary affinity group.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: April 3, 2018
    Assignee: The Scripps Research Institute
    Inventors: Matthew D. Disney, Lirui Guan, Wang-Yong Yang
  • Patent number: 9932326
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: April 3, 2018
    Assignees: Cocrystal Pharma, LLC, Emory University
    Inventors: Steven J. Coats, Franck Amblard, Hongwang Zhang, Longhu Zhou, Richard Anthony Whitaker, Tamara Rosario McBrayer, Raymond F. Schinazi, Junxing Shi
  • Patent number: 9931319
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: April 3, 2018
    Assignee: Novartis AG
    Inventors: Anne-Marie Edwards, Mahbub Ahmed, Robert Alexander Pulz, Lisa Ann Rooney, Nichola Smith, Thomas Josef Troxler
  • Patent number: 9932313
    Abstract: The invention provides pyrazolyl guanidine compounds that inhibit F1Fo-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: April 3, 2018
    Assignee: Lycera Corporation
    Inventors: Gary D. Glick, Alexander R. Hurd, Clarke B. Taylor, Chad A. VanHuis
  • Patent number: 9925201
    Abstract: The invention relates to compositions and methods for treating eye diseases and disorders. More specifically, the invention provides compositions comprising progesterone and methods of treating ocular surface diseases and disorders comprising applying such compositions topically.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: March 27, 2018
    Assignee: GLlA, LLC
    Inventors: Wei-Wei Chang, Kenneth Sawyer
  • Patent number: 9907800
    Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: March 6, 2018
    Assignee: University Health Network
    Inventors: Peter Brent Sampson, Yong Liu, Sze-Wan Li, Bryan T. Forrest, Heinz W. Pauls, Louise G. Edwards, Miklos Feher, Narendra Kumar B. Patel, Radoslaw Laufer
  • Patent number: 9873688
    Abstract: The present application is directed to processes and intermediates for making 4-({2-[(aminosulfonyl)amino]ethyl}amino)-N-(3-bromo-4-fluorophenyl)-N?-hydroxy-1,2,5-oxadiazole-3-carboximidamide, which is an inhibitor of indoleamine 2,3-dioxygenase, useful in the treatment of cancer and other disorders.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: January 23, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Ming Tao, William Frietze, David J. Meloni, Lingkai Weng, Jiacheng Zhou, Yongchun Pan
  • Patent number: 9868695
    Abstract: The present invention relates to the compounds of formula I wherein R is as herein described. The present invention particularly relates to synthesis and antiproliferative activity of 10-substituted colchicinoids. Compounds of the invention can be used for prevention or in the treatment of cancer disease.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: January 16, 2018
    Assignee: Council of Scientific & Industrial Research
    Inventors: Ram A. Vishwakarma, Sandip B. Bharate, Ajay Kumar, Baljinder Singh, Ashok Kumar, Shashi Bhushan, Abid Hamid, Prashant Joshi, Santosh K. Guru, Suresh Kumar, Aashiq Hussain, Asif K. Qazi, Sonali S. Bharate, Parduman Sharma, Ajit K. Saxena, Dilip M. Mondhe, Girish Mahajan, Zahoor Wani
  • Patent number: 9862705
    Abstract: The present invention relates to salt forms of the Pim kinase inhibitor N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of Pim kinase-related diseases such as cancer.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: January 9, 2018
    Assignee: Incyte Corporation
    Inventors: Zhongjiang Jia, Ganfeng Cao, Yongchun Pan, Vaqar Sharief, Jiacheng Zhou
  • Patent number: 9861971
    Abstract: The present invention concerns a process for creating a Carbon-Carbon bond (C—C) or a Carbon-Heteroatom bond (C—HE) by reacting a compound carrying a leaving group with a nucleophilic compound carrying a carbon atom or a heteroatom (HE) that can substitute for the leaving group, creating a C—C or C—HE bond, wherein the reaction takes place in the presence of an effective quantity of a. a catalytic system comprising a ligand and at least a metal-based catalyst, such a metal catalyst being chosen among iron or copper compounds proviso that only a single metal is present.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: January 9, 2018
    Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S)
    Inventors: Marc Taillefer, Ning Xia, Florian Monnier, Anis Tlili
  • Patent number: 9862676
    Abstract: A compound represented by general formula (1) (wherein R1 represents a hydrogen atom, an optionally substituted C1-6 alkyl group or the like; R2 represents a hydrogen atom, an optionally substituted C1-6 alkyl group or the like; R3 represents a hydrogen atom or an optionally substituted C1-6 alkyl group; R4 represents a hydrogen atom, an optionally substituted C1-6 alkyl group or the like; X1 represents an optionally substituted C2-6 alkynylene group or the like; A represents an optionally substituted bivalent aromatic hydrocarbon group or the like; X2 represents an optionally substituted C1-6 alkylene group or the like; Y1 represents an oxygen atom or the like; and R5 represents a hydrogen atom or the like) or a salt thereof is useful as an antibacterial agent.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 9, 2018
    Assignee: TOYAMA CHEMICAL CO., LTD.
    Inventors: Muneo Shoji, Naomi Sugaya, Naoko Yasobu
  • Patent number: 9855214
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: January 2, 2018
    Assignees: SILVERGATE PHARMACEUTICALS, INC, UNIVERSITY OF KANSAS
    Inventors: Lian G. Rajewski, Roger A. Rajewski, John L. Haslam, Kathleen Heppert, Michael C. Beckloff, Frank Segrave, Robert Mauro, Peter Colabuono
  • Patent number: 9855231
    Abstract: In various embodiments, methods and compositions for treating Raynaud's disease and Raynaud's phenomenon are provided. Topical administration of a semisolid composition comprising a prostaglandin E1 compound provides the desired relief of the Raynaud's disease or Raynaud's phenomenon without the possible complications of systemic administration. The semisolid composition can be administered as needed, or in a regimen of several doses per day.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: January 2, 2018
    Assignee: NEXMED HOLDINGS, INC.
    Inventors: Daniel W. Frank, Richard Martin, Bassam B. Damaj
  • Patent number: 9856262
    Abstract: Disclosed is a series of analogs of 4H-pyrazolo[1,5-?]benzimidazole compound as PARP inhibitors. In particular, disclosed in the invention is a compound as shown by formula (I) or a pharmaceutically acceptable salt thereof as a PARP inhibitor.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: January 2, 2018
    Assignees: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc., Humanwell Healthcare (Group) Co., Ltd., Medshine Discovery Inc.
    Inventors: Xuehai Wang, Zhaozhong Ding, Yong Xu, Shuhui Chen, Lie Li, Gang Li, Ronghua Tu, Cailin Wang, Yang Yue, Zhibo Zhang, Hailiang Chen, Wenjie Sun, Lu Huang
  • Patent number: 9850199
    Abstract: Isolated metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]-methyl]propanamide, methods for their use, and compositions containing the metabolites.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: December 26, 2017
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Marlene Michelle Dressman, Deepak Phadke
  • Patent number: 9850204
    Abstract: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: December 26, 2017
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Liming Shao, Fengjiang Wang, Scott C. Malcolm, Michael C. Hewitt
  • Patent number: 9849132
    Abstract: The present invention relates to a product comprising a PDE1 inhibitor and a PDE2 inhibitor, in free or salt form, pharmaceutical compositions comprising them and their use as pharmaceuticals for the treatment of cAMP and/or cGMP related disorders.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: December 26, 2017
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Joseph Hendrick, Jennifer O'Brien, Gretchen Snyder, Peng Li, Lawrence P. Wennogle